The cannabinoid framework.

Every cannabinoid that appears on a hemp or cannabis Certificate of Analysis is scored on two axes — altitude per mg (how much one milligram contributes to intensity, with Δ9-THC anchored at 3.0) and quadrant lean (how it distributes across the four compass quadrants: Calm, Clarity, Sustained, Sensory). Each score carries an evidence tier visible to the reader.

To place a product: read its COA, look up each cannabinoid in the table below, multiply each by its mg load in the product, sum the results, apply entourage modulation if applicable, divide by Δ9's anchor of 3.0 to get THC-equivalent mg, map to the altitude band. The quadrant lean is computed from the same weighted cannabinoid quadrant scores. The result is a reproducible placement on the 4×5 matrix.

Scoring table

Cannabinoid Altitude / mg Calm Clarity Sustained Sensory Confidence
Classical phytocannabinoids
Δ9-THC3.00.200.200.300.30STRONG
Δ8-THC2.00.300.150.350.20MODERATE
CBD0.20.550.200.200.05STRONG
CBG0.30.400.350.200.05MODERATE
CBN0.40.450.100.400.05LIMITED
CBC0.20.350.200.400.05LIMITED
CBDV0.10.400.400.150.05MODERATE
THCV (low, ≤7mg)0.30.100.550.300.05MODERATE
THCV (high, >10mg)2.50.150.300.300.25LIMITED
THCa (raw)0.10.450.300.200.05MODERATE
THCa (smoked)2.60.200.200.300.30STRONG
CBDa0.20.500.250.200.05LIMITED
Hemp-derived isomers & analogues
Δ10-THC1.80.100.450.250.20LIMITED
HHC2.40.250.200.300.25MODERATE
THC-O acetate4.00.100.100.300.50LIMITED
THC-P4.50.100.150.300.45LIMITED
THC-H3.80.150.200.300.35LIMITED
THC-B3.00.200.200.300.30LIMITED
11-OH-THC3.50.150.150.350.35STRONG
PHC3.00.150.150.400.30LIMITED

Quadrant weights sum to 1.0 per row. Altitudes are anchored to Δ9 = 3.0. Evidence tiers: STRONG = multiple peer-reviewed human studies; MODERATE = some peer-reviewed plus survey/observational data; LIMITED = preclinical or single-study with user reports filling gaps.

Entourage modulation

When a product's CBD:THC ratio is ≥ 1:1, apply a 0.85× multiplier to the THC altitude contribution and shift quadrant weight +0.05 toward Calm (subtract evenly from the other three, renormalize). Source: Russo 2011 (PMID 21749363); Freeman et al. 2019 systematic review (PMID 31412258).

Worked example.

A 5 mg Δ8 + 5 mg CBD + 2 mg CBG gummy:

Δ8 contribution = 5 × 2.0 = 10.0 alt
CBD contribution = 5 × 0.2 = 1.0 alt
CBG contribution = 2 × 0.3 = 0.6 alt
Raw sum = 11.6 alt
CBD:THC = 1:1 → apply 0.85× to Δ8: 10.0 → 8.5 → Adjusted = 10.1 alt
÷ Δ9 anchor (3.0) = 10.1 mg Δ9-equivalent → upper Balloon / lower Airplane

Quadrant lean computes to Calm 0.34 · Clarity 0.17 · Sustained 0.33 · Sensory 0.16 (after entourage shift). Calm and Sustained are nearly tied. By editorial judgment, the formulation context (evening gummy) lands at Decompress / Balloon, MODERATE confidence.

The botanical modifier module.

When a product's ingredient list includes non-cannabinoid actives — L-theanine, melatonin, ashwagandha, caffeine, lavender, etc. — we apply the Botanical Pharmacology Module v1 on top of the cannabinoid placement. Botanicals at the typical dose range in edibles and beverages (10–500 mg per serving) almost never push altitude. They shift the quadrant lean. The framework scores 28 commonly-used botanicals on three axes: a quadrant modifier vector, an effective-dose threshold, and a modifier intensity (0.02–0.18).

How botanicals compose with cannabinoid placement

After cannabinoids produce an initial quadrant vector Qcan, each botanical at effective dose contributes a pull toward its own vector:

Qfinal = (1 − Σ αi) · Qcannabinoid + Σ (αi · vi)

Where αi is the modifier intensity for botanical i, vi is its quadrant vector, and the cannabinoid share is capped so that botanicals never drive the cannabinoid contribution below 25%. Sub-clinically dosed botanicals (e.g. 50 mg ashwagandha in a gummy when the trial dose is 300 mg KSM-66) contribute zero — the framework treats them as marketing rather than active.

Scoring table — selected botanicals

Botanical Effective dose Calm Clarity Sustained Sensory Intensity Confidence
Calm / anxiolytic
L-theanine100–200 mg0.450.450.050.050.15STRONG
Chamomile (apigenin)200–1500 mg0.550.100.300.050.12MODERATE
Lavender (Silexan)80 mg0.550.100.300.050.15STRONG
Lemon balm300–600 mg0.550.150.250.050.12MODERATE
Passionflower250–500 mg0.550.100.300.050.10MODERATE
Ashwagandha (KSM-66)300–600 mg0.550.100.300.050.12MODERATE
Holy Basil / Tulsi300–600 mg0.500.200.250.050.10MODERATE
Energizing / focusing
Caffeine50–150 mg0.050.650.100.200.18STRONG
Yerba mate200–500 mg ext.0.200.550.100.150.15STRONG
Rhodiola rosea200–600 mg0.150.550.200.100.12MODERATE
B-vitamin complexnormal DV0.100.450.400.050.05MODERATE
Lion's Mane500–3000 mg0.200.550.200.050.08LIMITED
Cordyceps militaris1000–3000 mg0.100.500.350.050.08LIMITED
Bacopa monnieri300–600 mg0.200.500.250.050.05LIMITED (acute)
Sleep / sustained
Melatonin (low dose)0.3–1 mg0.450.050.500.000.18STRONG
Melatonin (high dose)3–10 mg0.450.050.500.000.15MODERATE
Valerian400–900 mg0.450.050.450.050.12MODERATE
Hops200–500 mg0.400.050.500.050.10MODERATE
Magnesium glycinate200–400 mg Mg0.550.100.300.050.08MODERATE
Other / weakly evidenced
Reishi1000–3000 mg0.550.100.300.050.08LIMITED
Schisandra500–2000 mg0.300.400.200.100.08LIMITED
Eleuthero300–1200 mg0.200.400.300.100.08LIMITED
Maca1500–3000 mg0.200.400.300.100.05LIMITED
Ginkgo biloba120–240 mg0.250.450.250.050.05LIMITED
Ginger250–1000 mg0.250.200.300.250.06LIMITED
Turmeric (+ piperine)500–2000 mg0.350.300.300.050.05LIMITED
5-HTP100–300 mg0.500.100.350.050.08LIMITED
GABA (oral)100–800 mg0.400.200.300.100.02LIMITED

28 botanicals scored. Intensities range 0.02–0.18. Sub-clinical doses contribute zero. Multiple botanicals from the same quadrant compound, capped at 0.50.

Worked example — a 5 mg Δ9 + 100 mg L-theanine + 50 mg caffeine drink

Step 1. Δ9-THC alone: 5 mg = 5.0 alt → Balloon band.
Quadrant from THC: Calm 0.20 / Clarity 0.20 / Sustained 0.30 / Sensory 0.30

Step 2. L-theanine 100 mg (effective dose ✓): α=0.15, vector (0.45, 0.45, 0.05, 0.05)
Caffeine 50 mg (effective dose ✓): α=0.18, vector (0.05, 0.65, 0.10, 0.20)
Total α = 0.33, cannabinoid share = 0.67

Step 3. Qfinal = 0.67·(0.20, 0.20, 0.30, 0.30) + 0.15·(0.45, 0.45, 0.05, 0.05) + 0.18·(0.05, 0.65, 0.10, 0.20)
= (0.211, 0.317, 0.227, 0.245) — Clarity dominant.

Step 4. Pillar = Clarity. Altitude = Balloon. Confidence = STRONG.

The combination of L-theanine's calm-alert character and caffeine's stimulating pull on a low-THC base produces a daytime functional drink — exactly the "calm focus" category the formulation is engineered for. The framework agrees with the design intent.

The terpene reference.

Eleven terpenes form the standard reportable panel in commercial cannabis labs and define our chemical space for Atlas projections. Each carries a documented aroma profile and a contested-but-suggestive effect register.

Myrcene MYR
earthy · musky · herbal
Caryophyllene CAR
spicy · woody · pepper
Limonene LIM
citrus · lemon · orange
Terpinolene TER
piney · floral · fresh
α-Pinene PIN
pine · fresh · forest
Linalool LIN
floral · lavender · sweet
β-Pinene BPN
pine · woody · green
Humulene HUM
hoppy · earthy · woody
Nerolidol NER
floral · waxy · citrus
Ocimene OCI
sweet · herbaceous · woody
Bisabolol BIS
floral · chamomile · sweet

The Atlas.

Phytonomy — the analytical engine behind Altitude Control — maps 2,257 named cultivars from the Pestele 2022 dataset into a 2-dimensional chemical space using PCA on L2-normalized 11-dimensional terpene fingerprints. Cosine similarity operates within this space. Chemotype clusters emerge naturally.

Open the engine

Explore the chemistry.

The Atlas is the receipts behind everything else on this site. Drag the similarity threshold, color nodes by chemotype, compose a custom blend, find your strain's neighbors in chemical space.

Open the Atlas →

Primary sources.

  • Pestele et al. 2022 (PLoS ONE, PMID 35576208) — Atlas chemistry dataset
  • Tagen & Klumpers 2022 (Br J Pharmacol, DOI 10.1111/bph.15865) — Δ8 review
  • Pertwee 2008 (PMID 18204467) — CB1 / CB2 binding affinities
  • Cascio et al. 2010 (PMID 19751305) — CBG α2-adrenergic mechanism
  • Corroon 2021 (DOI 10.1089/can.2021.0006) — CBN sedation review (negative result)
  • Citti et al. 2019 (DOI 10.1038/s41598-019-56785-1) — THC-P discovery and CB1 affinity
  • Nasrallah & Garg 2023 (DOI 10.1038/s41598-023-38188-5) — HHC epimer pharmacology
  • Russo 2011 (PMID 21749363) — entourage effect review
  • Freeman et al. 2019 (PMID 31412258) — CBD/THC modulation systematic review
  • Lucas et al. 2018 (PMC6177698) — cannabinoid pharmacokinetics
  • Wang et al. 2016 — THCa decarboxylation efficiency
  • Munger et al. 2023 (J Med Toxicol) — THC-O ketene formation hazard